Unknown

Dataset Information

0

MiRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin.


ABSTRACT: Cisplatin resistance is a major obstacle in the treatment of NSCLC, and its mechanism has not been fully elucidated. The objectives of the study were to determine the role of miR-378 in the sensitivity of lung adenocarcinoma cells to cisplatin (cDDP) and its working mechanism. With TargetScan and luciferase assay, miR-378 was found to directly target sCLU. miR-378 and sCLU were regulated in A549/cDDP and Anip973/cDDP cells to investigate the effect of miR-378 on the sensitivity and apoptotic effects of cDDP. The effect of miR-378 upregulation on tumor growth was analyzed in a nude mouse xenograft model. The correlation between miR-378 and chemoresistance was tested in patient samples. We found that upregulation of miR-378 in A549/cDDP and Anip973/cDDP cells significantly down-regulated sCLU expression, and sensitized these cells to cDDP. miR-378 overexpression inhibited tumor growth and sCLU expression in a xenograft animal model. Analysis of human lung adenocarcinoma tissues revealed that the cDDP sensitive group expressed higher levels of miR-378 and lower levels of sCLU. miR-378 and sCLU were negatively correlated. To conclude, we identified sCLU as a novel miR-378 target, and we showed that targeting sCLU via miR-378 may help disable the chemoresistance against cisplatin in lung adenocarcinoma cells.

SUBMITTER: Chen X 

PROVIDER: S-EPMC4725983 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8093570 | biostudies-literature
| S-EPMC10866401 | biostudies-literature
| S-EPMC5217899 | biostudies-literature
| S-EPMC4102932 | biostudies-literature
| S-EPMC7138577 | biostudies-literature
| S-EPMC9066100 | biostudies-literature
| S-EPMC2928515 | biostudies-other
| S-EPMC6838973 | biostudies-literature
| S-EPMC7505950 | biostudies-literature
| S-EPMC7027123 | biostudies-literature